Postmenopausal osteoporosis therapy reshapes around anabolic-first sequencing
Romosozumab maturity, ongoing teriparatide and abaloparatide use, and follow-on anabolic programs are restructuring postmenopausal osteoporosis sequencing.
Postmenopausal osteoporosis has been a bisphosphonate-and-denosumab category for years, with anabolic options reserved for severe disease. Romosozumab maturity, follow-on anabolic programs, and growing recognition that anabolic-first sequencing improves bone density and fracture outcomes more than anti-resorptive-first are reshaping the category. The diagnostic-pathway question (DXA scanning, fracture risk assessment, post-fracture care) is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.